Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710046 · ClinicalTrials.gov registry record · Phase 2
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01710046 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT01710046, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.
Interventions
- DRUG Placebo
- DRUG (CP-6890,550) Tofacitinib
- DRUG (CP-690,550) Tofacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710046
The ClinicalTrials.gov registry entry for NCT01710046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01710046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710046 about?
NCT01710046 is a clinical study titled "Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis". There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.
What is the current status of trial NCT01710046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01710046?
The interventions under investigation include: Placebo (DRUG), (CP-6890,550) Tofacitinib (DRUG), (CP-690,550) Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01710046?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.